Osegi
Science·2 min read

VCN-01: a modified cold virus against pancreatic cancer

A Madrid-led trial used a genetically modified cold virus to break through pancreatic tumours' protective wall. Patients lived 10.8 months versus 8.6 on chemo alone.

Researcher in a lab examining a sample under a microscope in a cancer research setting.
Image: xataka.com

Pancreatic cancer is one of the deadliest cancers, partly because the tumour builds a kind of armour around itself. A clinical trial led by Madrid's Hospital 12 de Octubre now suggests a modified cold virus called VCN-01 can help tear that armour down.

What is VCN-01?

VCN-01 is an adenovirus, the family of viruses behind common colds, redesigned by VCN Biosciences, a Barcelona start-up. It has been modified so the liver, the body's big filter, doesn't destroy it after an injection. That lets it travel through the blood and reach both the main tumour and metastases.

Once inside cancer cells, the virus replicates and kills them. It also produces an enzyme called hyaluronidase, which breaks down the hyaluronic acid in the tumour's wall. The idea is to open a path for chemotherapy, a bit like a Trojan horse.

Why is pancreatic cancer so hard to treat?

Pancreatic ductal adenocarcinoma generates an extremely dense, fibrous matrix around itself. It works as a physical shield: chemo drugs struggle to get in, and immune cells that could attack the tumour are kept out.

What did the trial find?

Researchers compared standard treatment with standard treatment plus the virus. Patients who received the virus and chemotherapy had a median overall survival of 10.8 months. Those on chemotherapy alone had 8.6 months.

There is a catch. The statistical significance sits right at the edge of what science counts as significant. That is not a verdict, but it is a reason to run larger trials with more patients to see whether the benefit holds.

The road here was long. In 2021, a phase 1 trial led by Marta Bazan-Peregrino showed that injecting the virus directly into the tumour was well tolerated and stabilised the treated lesions. In 2022, another phase 1 study led by Dr Rocío García-Carbonero found a 50% overall response rate with intravenous administration in pancreatic adenocarcinoma patients. Viral genomes were also detected in tumour tissue in five of six biopsies analysed.

Apps worth a look

SUMO: the number puzzle

Tap the right tiles, add them up, hit the target. Easy to learn, hard to master. Free, for all ages.

Tags:pancreatic cancervcn-01adenovirushospital 12 de octubreclinical trialoncolytic virus

More from this day

See all →

More in: Science

See all →